Reunion Neuroscience (TSE:REUN – Get Rating) was downgraded by research analysts at Stifel Nicolaus from a “speculative buy” rating to a “hold” rating in a report issued on Wednesday, BayStreet.CA reports.
Several other brokerages have also commented on REUN. HC Wainwright restated a “buy” rating and issued a C$20.00 price objective on shares of Reunion Neuroscience in a report on Thursday, January 19th. Roth Capital began coverage on shares of Reunion Neuroscience in a report on Friday, December 16th. They issued a “buy” rating and a C$11.00 price objective on the stock.
Reunion Neuroscience Stock Up 5.1 %
TSE:REUN opened at C$1.23 on Wednesday. The firm has a market cap of C$14.33 million, a price-to-earnings ratio of -0.19 and a beta of 4.10. The company has a 50-day moving average price of C$1.59. Reunion Neuroscience has a 1-year low of C$1.05 and a 1-year high of C$10.50.
Reunion Neuroscience Company Profile
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions.
Featured Articles
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Reunion Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reunion Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
